Phio pharmaceuticals announces presentation at the 9th annual car-tcr summit in boston, ma

Phio's intasyl self-delivering rnai technology enhances cell potency and yield in adoptive cell therapy marlborough, massachusetts--(newsfile corp. - september 16, 2024) - phio pharmaceuticals corp. (nasdaq: phio), a clinical stage biotechnology company whose proprietary intasyl® sirna gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that it is presenting data about its intasyl technology platform which represents an innovative and flexible solution for adoptive cell therapy providing compounds designed specifically to enhance cell potency and improve overall yield, offering a more effective approach for treating cancer. the data will be presented at the car-tcr summit taking place september 17-20 in boston, ma.
CAR Ratings Summary
CAR Quant Ranking